Chicago, IL—New research presented at the American Association for Cancer Research annual congress suggests a single dose of the human papillomavirus (HPV) vaccine may provide sufficient protection against HPV infections. This finding challenges the current recommendation in developed countries, which advises two doses for young people, typically around age 11, before they become sexually active.

HPV infections are highly contagious and primarily transmitted through sexual contact. These infections can lead to precancerous lesions, which, depending on their location, can develop into cervical, anal, penile, or oropharyngeal (ENT) cancers.

Implications for Global Vaccination Efforts

The study’s findings could substantially impact global vaccination efforts, particularly in regions with limited resources. As Stnews noted, This result could make it possible to achieve the vaccination target of three-quarters of adolescents around the world.

Norman Sharpless, former director of the National Cancer Institute, emphasized the importance of this research. I think this is the most crucial current clinical trial on cancer prevention. Now we have a long story of failure in this field, Sharpless told Stnews. He added:

It’s grate to have such clear evidence to support our practice. It will make the papillomavirus vaccine around the world much easier and less expensive – and above all, this will save millions of lives.
Norman Sharpless, Former Director of the National Cancer Institute

Costa Rica Study Details

The study, conducted in Costa Rica, involved 20,000 young women who were randomly assigned to receive either one or two doses of an HPV vaccine. Participants were monitored for over four years. The results indicated that a single dose of the vaccine was just as effective as two doses, with both regimens demonstrating an efficacy rate exceeding 97%.